ATE383168T1 - Fgf-2 zur behandlung von erkrankungen der peripheralen arterien - Google Patents

Fgf-2 zur behandlung von erkrankungen der peripheralen arterien

Info

Publication number
ATE383168T1
ATE383168T1 AT01946663T AT01946663T ATE383168T1 AT E383168 T1 ATE383168 T1 AT E383168T1 AT 01946663 T AT01946663 T AT 01946663T AT 01946663 T AT01946663 T AT 01946663T AT E383168 T1 ATE383168 T1 AT E383168T1
Authority
AT
Austria
Prior art keywords
fgf
peripheral artery
artery disease
compositions
patient
Prior art date
Application number
AT01946663T
Other languages
English (en)
Inventor
Martha Whitehouse
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE383168T1 publication Critical patent/ATE383168T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01946663T 2000-06-22 2001-06-22 Fgf-2 zur behandlung von erkrankungen der peripheralen arterien ATE383168T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21350400P 2000-06-22 2000-06-22
US26457201P 2001-01-26 2001-01-26
US27654901P 2001-03-16 2001-03-16
US09/886,856 US20020115603A1 (en) 2000-06-22 2001-06-21 Methods and compositions for the treatment of peripheral artery disease

Publications (1)

Publication Number Publication Date
ATE383168T1 true ATE383168T1 (de) 2008-01-15

Family

ID=27498936

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01946663T ATE383168T1 (de) 2000-06-22 2001-06-22 Fgf-2 zur behandlung von erkrankungen der peripheralen arterien

Country Status (8)

Country Link
US (3) US20020115603A1 (de)
EP (1) EP1324766B1 (de)
JP (1) JP2004501164A (de)
AT (1) ATE383168T1 (de)
AU (1) AU2001268680A1 (de)
CA (1) CA2414020A1 (de)
DE (1) DE60132343T2 (de)
WO (1) WO2001098346A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166550A1 (en) 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US20020115603A1 (en) * 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
US20030004753A1 (en) * 2001-06-27 2003-01-02 Blackshear William M. Management method of persons at risk of complications of arterial occlusive disease
JP4583763B2 (ja) * 2002-04-08 2010-11-17 ザ スクリップス リサーチ インスティチュート 切断型２４ｋＤａ塩基性線維芽細胞成長因子
JP4532092B2 (ja) * 2003-09-30 2010-08-25 泰彦 田畑 血管新生剤
US7346382B2 (en) 2004-07-07 2008-03-18 The Cleveland Clinic Foundation Brain stimulation models, systems, devices, and methods
AU2006263669B9 (en) * 2005-06-29 2012-12-13 Mars, Incorporated Inducing peripheral blood vessel vasodilation
US20090062309A1 (en) * 2007-08-28 2009-03-05 Antonio Delgado-Almeida Therapeutic compositions for the treatment of cardiovascular diseases and methods for use therefor
US8812123B2 (en) * 2007-10-17 2014-08-19 Intelect Medical, Inc. Patient programmer with input and sensing capabilities
US9220889B2 (en) 2008-02-11 2015-12-29 Intelect Medical, Inc. Directional electrode devices with locating features
US8019440B2 (en) 2008-02-12 2011-09-13 Intelect Medical, Inc. Directional lead assembly
US9272153B2 (en) 2008-05-15 2016-03-01 Boston Scientific Neuromodulation Corporation VOA generation system and method using a fiber specific analysis
WO2010054265A2 (en) 2008-11-07 2010-05-14 Galaxy Biotech, Llc. Monoclonal antibodies to fibroblast growth factor receptor 2
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
EP2470258B1 (de) 2009-08-27 2017-03-15 The Cleveland Clinic Foundation System und verfahren zur beurteilung einer gewebeaktivierungsregion
WO2011068997A1 (en) 2009-12-02 2011-06-09 The Cleveland Clinic Foundation Reversing cognitive-motor impairments in patients having a neuro-degenerative disease using a computational modeling approach to deep brain stimulation programming
AU2011239386B2 (en) 2010-04-16 2015-03-19 Salk Institute For Biological Studies Methods for treating metabolic disorders using FGF
WO2011159688A2 (en) 2010-06-14 2011-12-22 Boston Scientific Neuromodulation Corporation Programming interface for spinal cord neuromodulation
EP2691898A2 (de) 2011-03-29 2014-02-05 Boston Scientific Neuromodulation Corporation System und verfahren zur atlasaufzeichnung
US9592389B2 (en) 2011-05-27 2017-03-14 Boston Scientific Neuromodulation Corporation Visualization of relevant stimulation leadwire electrodes relative to selected stimulation information
CA2844075A1 (en) 2011-08-09 2013-02-14 Boston Scientific Neuromodulation Corporation Systems and methods for stimulation-related volume analysis, creation, and sharing
EP2879757B1 (de) 2012-08-04 2019-06-26 Boston Scientific Neuromodulation Corporation Systeme und verfahren zum speichern und übertragen von registrierungen sowie atlas- und anleitungsinformationen zwischen medizinischen vorrichtungen
WO2014036079A2 (en) 2012-08-28 2014-03-06 Boston Scientific Neuromodulation Corporation Parameter visualization, selection, and annotation interface
US9792412B2 (en) 2012-11-01 2017-10-17 Boston Scientific Neuromodulation Corporation Systems and methods for VOA model generation and use
US10342551B2 (en) * 2013-07-12 2019-07-09 Vasoinnovations Inc. Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant
US10888334B2 (en) 2013-07-12 2021-01-12 Vasoinnovations Inc. Apparatus and method to stop bleeding
US9949738B2 (en) 2013-07-12 2018-04-24 Vasoinnovations, Inc. Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant
US10213214B2 (en) * 2013-07-12 2019-02-26 Vasoinnovations, Inc. Method to stop bleeding, with short hemostasis duration using a low dose of anticoagulant
US11564697B2 (en) 2013-07-12 2023-01-31 Vasoinnovations Inc. Apparatus and method to stop bleeding
US9668744B2 (en) 2015-08-05 2017-06-06 Vasoinnovations, Inc. Apparatus and method to stop bleeding
US9308000B2 (en) 2013-07-12 2016-04-12 Vasoinnovations, Inc. Method of transradial catheterization, device for ulnar artery compression, and method of use
US9332994B2 (en) 2013-07-12 2016-05-10 Vasoinnovations, Inc. Apparatus and method to stop bleeding
WO2015061331A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
US9959388B2 (en) 2014-07-24 2018-05-01 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for providing electrical stimulation therapy feedback
US10272247B2 (en) 2014-07-30 2019-04-30 Boston Scientific Neuromodulation Corporation Systems and methods for stimulation-related volume analysis, creation, and sharing with integrated surgical planning and stimulation programming
US10265528B2 (en) 2014-07-30 2019-04-23 Boston Scientific Neuromodulation Corporation Systems and methods for electrical stimulation-related patient population volume analysis and use
US9974959B2 (en) 2014-10-07 2018-05-22 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters
WO2016191436A1 (en) 2015-05-26 2016-12-01 Boston Scientific Neuromodulation Corporation Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation
US10780283B2 (en) 2015-05-26 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation
WO2017003946A1 (en) 2015-06-29 2017-01-05 Boston Scientific Neuromodulation Corporation Systems and methods for selecting stimulation parameters based on stimulation target region, effects, or side effects
US10441800B2 (en) 2015-06-29 2019-10-15 Boston Scientific Neuromodulation Corporation Systems and methods for selecting stimulation parameters by targeting and steering
EP3359252B1 (de) 2015-10-09 2020-09-09 Boston Scientific Neuromodulation Corporation System und verfahren zur kartierung klinischer wirkungen für direktionale stimulationselektroden
WO2017127493A1 (en) * 2016-01-22 2017-07-27 Salk Institute For Biological Studies Fgf2 truncations and mutants and uses thereof
US10716942B2 (en) 2016-04-25 2020-07-21 Boston Scientific Neuromodulation Corporation System and methods for directional steering of electrical stimulation
AU2017281934B2 (en) 2016-06-24 2019-11-14 Boston Scientific Neuromodulation Corporation Systems and methods for visual analytics of clinical effects
WO2018044881A1 (en) 2016-09-02 2018-03-08 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and directing stimulation of neural elements
US10780282B2 (en) 2016-09-20 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for steering electrical stimulation of patient tissue and determining stimulation parameters
WO2018071865A1 (en) 2016-10-14 2018-04-19 Boston Scientific Neuromodulation Corporation Systems and methods for closed-loop determination of stimulation parameter settings for an electrical simulation system
CN110167629B (zh) 2017-01-03 2023-07-18 波士顿科学神经调制公司 用于选择兼容mri的刺激参数的系统和方法
US10589104B2 (en) 2017-01-10 2020-03-17 Boston Scientific Neuromodulation Corporation Systems and methods for creating stimulation programs based on user-defined areas or volumes
US10625082B2 (en) 2017-03-15 2020-04-21 Boston Scientific Neuromodulation Corporation Visualization of deep brain stimulation efficacy
US11357986B2 (en) 2017-04-03 2022-06-14 Boston Scientific Neuromodulation Corporation Systems and methods for estimating a volume of activation using a compressed database of threshold values
EP3615560A4 (de) * 2017-04-26 2020-12-23 University of Cincinnati Zusammensetzungen von fibroblastenwachstumsfaktorliganden und verfahren zur behandlung von patienten mit ischämie-reperfusionstherapie
JP6932835B2 (ja) 2017-07-14 2021-09-08 ボストン サイエンティフィック ニューロモデュレイション コーポレイション 電気刺激の臨床効果を推定するシステム及び方法
EP3634569A1 (de) 2017-08-15 2020-04-15 Boston Scientific Neuromodulation Corporation Systeme und verfahren zur steuerung der elektrischen stimulation unter verwendung von mehreren stimulationsfeldern
JP7295141B2 (ja) 2018-04-27 2023-06-20 ボストン サイエンティフィック ニューロモデュレイション コーポレイション マルチモード電気刺激システム及び製造する及び使用する方法
US11285329B2 (en) 2018-04-27 2022-03-29 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and programming electrical stimulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604293A (en) 1985-09-12 1997-02-18 Scios Inc. Recombinant human basic fibroblast growth factor
US5852177A (en) 1987-02-24 1998-12-22 Takeda Chemical Industries, Ltd. Basic fibroblast growth factor (bFGF) muteins
ES2155534T3 (es) 1994-10-12 2001-05-16 Focal Inc Administracion dirigida por medio de polimeros biodegradables.
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
EP0871512A1 (de) 1995-12-22 1998-10-21 Localmed, Inc. Lokale intravaskuläre abgabe von wachsfaktoren zur stimulierung von angiogenese
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
ES2327839T3 (es) * 1998-09-03 2009-11-04 Novartis Vaccines And Diagnostics, Inc. Monodosis de fgf-2 eficaz angiogenicamente y metodo de uso.
US20030166550A1 (en) 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
AU6411199A (en) 1998-10-13 2000-05-01 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
US20020072489A1 (en) 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US6440934B1 (en) 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020115603A1 (en) 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease

Also Published As

Publication number Publication date
DE60132343D1 (de) 2008-02-21
WO2001098346A3 (en) 2003-05-01
US7541337B2 (en) 2009-06-02
US7186407B2 (en) 2007-03-06
US20020115603A1 (en) 2002-08-22
EP1324766B1 (de) 2008-01-09
JP2004501164A (ja) 2004-01-15
WO2001098346A2 (en) 2001-12-27
EP1324766A2 (de) 2003-07-09
AU2001268680A1 (en) 2002-01-02
US20040209817A1 (en) 2004-10-21
DE60132343T2 (de) 2008-12-24
CA2414020A1 (en) 2001-12-27
US20070135348A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
ATE383168T1 (de) Fgf-2 zur behandlung von erkrankungen der peripheralen arterien
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
PT710114E (pt) Formulacao do factor viii de coagulacao
ATE432289T1 (de) Glp-1 und behandlungsmethode für diabetes
BR9507227A (pt) Formulaçao farmacêutica para administraçao subcutânea intramuscular ou intradérmica uso da mesma e de um derivado de extinçao de um fator recombinante VIII e processo para o tratamento de hemofilia
DE69533112D1 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
WO2001027079A3 (en) Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
WO2000021548A3 (en) Angiogenically effective unit dose of fgf and method of administering
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
HK1075409A1 (en) Angiogenically effective unit dose of fgf-2 and method of use fgf-2
DE69739050D1 (de) Verwendung von Thrombopoietin als Medikament zur Therapie und Vorbeugung der Thrombocytopenie
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
WO2002058720A3 (en) Angiogenically effective unit dose of fgf-2 and method of use
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
KR101255200B1 (ko) 자가면역 손상에 따른 중추 신경계의 신경 재생용ｅｇｆ/ｇｈｒｐ-6의 조합
EP1894570A3 (de) Verfahren und Zusammensetzungen zur Behandlung von Erkrankungen der peripheren Arterie
RU2130773C1 (ru) Способ лечения саркомы капоши
RU2140270C1 (ru) Способ лечения идиопатического типа саркомы капоши
RU2020123217A (ru) Противо-SARS-CoV-2 вирусное средство Антипровир
RU2021130022A (ru) Применение эпидермального фактора роста при лечении диабетической язвы стопы
ATE280584T1 (de) Verwendung von beta interferon zur herstellung eines arzneimittels zur behandlung von ewings sarkom und eoe
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties